Barinthus Biotherapeutics Ownership | Who Owns Barinthus Biotherapeutics?
Barinthus Biotherapeutics Ownership Summary
Barinthus Biotherapeutics is owned by 25.17% institutional investors, and 74.83% retail investors.
VACC Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Barinthus Biotherapeutics | 25.17% | - | 74.83% |
Sector | Healthcare Stocks | 47.06% | 8.01% | 44.93% |
Industry | Biotech Stocks | 44.97% | 7.82% | 47.21% |
Institutional Shareholders
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Mar 31, 2024 | 15 | - | 9,698,209 | -0.20% | 25 | 3.96% | 2 | -33.33% | 3 | 50.00% |
Dec 31, 2023 | 15 | -6.25% | 9,718,135 | 0.12% | 25 | 3.97% | 3 | -25.00% | 2 | -33.33% |
Sep 30, 2023 | 16 | 6.67% | 9,706,658 | -1.43% | 25 | 3.83% | 4 | -20.00% | 3 | 50.00% |
Jun 30, 2023 | 15 | 15.38% | 9,847,143 | -3.54% | 25 | 3.53% | 5 | - | 2 | 100.00% |
Mar 31, 2023 | 13 | -13.33% | 10,208,776 | -0.19% | 26 | 3.57% | 5 | - | 1 | -66.67% |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Jun 26, 2023 | Scheeren Joseph | - | Buy | $24.40K |
May 25, 2023 | Wright Robin | - | Buy | $36.61K |
Mar 27, 2023 | Enright William | Chief Executive Officer | Sell | $36.30K |
Aug 25, 2022 | Griffiths Graham | Chief Business Officer | Sell | $73.87K |
Aug 24, 2022 | Ellis Christopher | Chief Operating Officer | Sell | $176.71K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2024 Q1 | - | - |
2023 Q2 | 2 | - |
2023 Q1 | - | 1 |
2022 Q3 | - | 7 |
2022 Q2 | 1 | 2 |
VACC Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools